SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddys Lab gains on launching Valganciclovir Tablets

17 Dec 2014 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 3160.65, up by 19.35 points 0.74 % from its previous closing of Rs. 3142.05 on the BSE.

The scrip opened at Rs. 3117.00 and has touched a high and low of Rs  3178.80 and Rs  3060.00  respectively. So far 26,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3662.00 on 01-Dec-2014 and a 52 week low of Rs. 2250.00 on 19-May-2014.

Last one week high and low of the scrip stood at Rs. 3448.00 and Rs. 3,060.00 respectively. The current market cap of the company is Rs. 54,006.96 crore.

The promoters holding in the company stood at 25.49 % while Institutions and Non-Institutions held 43.79 % and 13.69 % respectively.

Dr. Reddy’s Laboratories has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of Valcyte (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA). The company’s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60.

The Valcyte (Valganciclovir) tablets brand had U.S. sales of around $440 million MAT for the most recent twelve months ending in October 2014, according to IMS Health.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1220.75 -11.50 (-0.93%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×